LONDON, UK - Sep 19, 2019 - QVigilance, a global provider of pharmacovigilance (PV) and risk management services, has announced a preferred partnership agreement with medical information (MI) provider ESMS Global. 

QVigilance specialise in establishing and maintaining comprehensive and compliant PV systems and services for small and mid-size biopharmaceutical companies.

The services are complemented by ESMS, which provides 24/7 medical monitoring services for clinical trials and MI services for authorised products.

The two companies have been working together for over two years on mutual projects and developed a relationship which enables a seamless exchange and reconciliation of safety information arising from medical enquiries and product quality complaints.

David Hukin, managing director at QVigilance, said: “Our shared values and proven track record in delivering exceptional quality services for our mutual clients and the synergy between our teams has laid down the basis for this successful partnership.

“By putting the agreement in place, both ESMS Global and QVigilance will offer customers access to a broader set of capabilities and a more efficient and cost-effective service.

“It marks a significant opportunity for both companies to be able to support clients seeking comprehensive and bespoke PV and medical information services.”

Rita Fitzpatrick, general manager at ESMS Global, added: “ESMS Global is delighted to partner with QVigilance. This partnership brings together two well-established, expert companies allowing clients to have one contract covering both MI and PV services making the process of outsourcing and oversight of service providers easier and more efficient”.